Supplementary Figure 2 from Antibody-Mediated Delivery of Anti–KRAS-siRNA In Vivo Overcomes Therapy Resistance in Colon Cancer
software
posted on 2023-03-31, 17:46 authored by Sebastian Bäumer, Nicole Bäumer, Neele Appel, Lisa Terheyden, Julia Fremerey, Sonja Schelhaas, Eva Wardelmann, Frank Buchholz, Wolfgang E. Berdel, Carsten Müller-TidowSupplementary Figure 2. Anti-EGFR antibody-directed EZH2-RNAi reduces EZH2 expression in EGFR-expressing carcinoma cell lines/overview of cell lines used in this study.
History
ARTICLE ABSTRACT
Purpose: KRAS mutations are frequent driver mutations in multiple cancers. KRAS mutations also induce anti-EGFR antibody resistance in adenocarcinoma such as colon cancer. The aim of this study was to overcome anti-EGFR antibody resistance by coupling the antibody to KRAS-specific siRNA.Experimental Design: The anti-EGFR antibody was chemically coupled to siRNA. The resulting complex was tested for antibody binding efficiency, serum stability and ability to deliver siRNA to EGFR-expressing cells. Western blotting, viability, apoptosis, and colony formation assays were performed for efficacy evaluation in vitro. Furthermore, therapeutic activity of the antibody–KRAS-siRNA complexes was examined in in vivo xenograft mouse tumor models.Results: Antibody–siRNA complexes were targeted and internalized via the EGFR receptor. Upon internalization, target gene expression was strongly and specifically repressed, followed by a reduced proliferation and viability, and induced apoptosis of the cells in vitro. Clonogenic growth of mutant KRAS-bearing cells was suppressed by KRAS-siRNA–anti-EGFR antibody complexes. In xenograft mouse models, anti-EGFR antibody–KRAS-siRNA complexes significantly slowed tumor growth in anti-EGFR–resistant cells.Conclusions: The coupling of siRNA against KRAS to anti-EGFR antibodies provides a novel therapy approach for KRAS-mutated EGFR-positive cancer cells in vitro and in vivo. These findings provide an innovative approach for cancer-specific siRNA application and for enhanced therapeutic potential of monoclonal antibody therapy and personalized treatment of cancer entities. Clin Cancer Res; 21(6); 1383–94. ©2015 AACR.Usage metrics
Categories
Keywords
Biological Agents & TherapiesAntisense oligonucleotidesCarcinogenesisSignal transductionCell CycleSignal transduction pathwaysCell SignalingProtein tyrosine kinasesDrug ResistanceClinical drug resistanceDrug TargetsProtein kinase & phosphatase drug targetsGastrointestinal CancersColorectal cancerImmunologyAntibodies/immunoconjugatesPreclinical ModelsXenograft models
Licence
Exports
RefWorksRefWorks
BibTeXBibTeX
Ref. managerRef. manager
EndnoteEndnote
DataCiteDataCite
NLMNLM
DCDC